TY - JOUR AU - Memon, Roomi Aijaz AU - Kazi, Navaid AU - Uquili, Arsalan AU - Memon, Hinna AU - Memon, Aijaz Ali PY - 2019/03/31 Y2 - 2024/03/29 TI - EFFECTS OF INTERLEUKIN 1 INHIBITOR ON INFLAMMATORY CYTOKINES TNF-ALPHA LEVELS IN DIABETIC ALBINO WISTAR RAT MODEL JF - Pakistan Journal of Physiology JA - Pak J Phsyiol VL - 15 IS - 1 SE - Original Article DO - UR - https://pjp.pps.org.pk/index.php/PJP/article/view/1072 SP - 3-6 AB - <p><strong>Background: </strong>Diacerein is a second generation Interleukin-1 inhibitor (IL-1). IL-1 and Tumour Necrosis Factor Alpha (TNF-?), are inhibitors of the pancreatic ?-cells secretory activity and proliferation. There is need to test Diacerein on IL-1-TNF-? axis to improves the ?-cell functions and proliferation. This study was designed to determine the relation of inflammatory markers and diabetes mellitus in interleukin 1 inhibitors treated albino Wistar rat models.<strong> Methods:</strong> A sample of 60 albino Wistar rats, selected by convenient purposive sampling, was divided into 4 groups: Group A (Controls), Group B (given Alloxan 50 mg/Kg, i.p.), Group C (Diabetic rats given Diacerein 30 mg/Kg for 21 days) and Group D (Diabetic rats given Diacerein 50 mg/Kg for 21 days). &nbsp;The data was analyzed using SPSS-22. <strong>Results: </strong>The Mean±SD of blood glucose in the groups A, B, C, and D was noted as 113.66±10.67, 253.19±63.71, 215.23±36.32 and 178.0±16.52 mg/dl respectively (F=36.77, <em>p</em>=0.010). The Mean±SD of HbA1c in the groups A, B, C and D was noted as 4.14±0.86, 9.85±0.97, 7.52±0.78 and 6.71±1.02 mg/dl respectively (F=69.58, <em>p</em>=0.018). The Mean±SD of TNF-? in the groups A, B, C, and D was noted as 14.99±4.14, 37.85±3.61, 32.74±4.09, and 26.24±2.64 mg/dl respectively. <strong>Conclusion</strong><strong>:</strong> Our findings suggested that inflammatory markers (TNF-?) were decrease and good glycaemic control &nbsp;&nbsp;with interleukin 1 inhibitors (Diacerein) treated diabetic rats.</p><p><strong>Keywords:</strong> Interleukin-1 inhibitor, Alloxan, Diabetes Mellitus, TNF-?</p><p><strong>Pak J Physiol 2019;</strong>15(1):3–6</p> ER -